Full Text Journal Articles by
Author Ruben Pio

Advertisement

Find full text journal articles






Editorial: The Role of Complement in Tumors.

Barbara E Rolfe, Ruben Pio, Trent M Woodruff, Maciej M Markiewski, Helga D Manthey,

Front Immunol (Frontiers in Immunology)
[2020, 11:139]

Cited: 0 times

View full text PDF listing >>



TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients.

Maria Villalba, Francisco Exposito, Maria Jose Pajares, Cristina Sainz, Miriam Redrado, Ana Remirez, Ignacio Wistuba, Carmen Behrens, Eloisa Jantus-Lewintre, Carlos Camps, Luis M Montuenga, Ruben Pio, Maria Dolores Lozano, Carlos de Andrea, Alfonso Calvo,

Relapse rates in surgically resected non-small-cell lung cancer (NSCLC) patients are between 30% and 45% within five years of diagnosis, which shows the clinical need to identify those patients at high risk of recurrence. The eighth TNM staging system recently refined the classification of NSCLC patients and their associated prognosis, ... Read more >>

J Clin Med (Journal of clinical medicine)
[2019, 8(12):]

Cited: 0 times

View full text PDF listing >>



Advertisement

'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, Mohamed R Daha, Brian V Geisbrecht, Berhane Ghebrehiwet, Piet Gros, George Hajishengallis, V Michael Holers, Markus Huber-Lang, Taroh Kinoshita, Tom E Mollnes, Robert A Montgomery, B Paul Morgan, Bo Nilsson, Ruben Pio, Daniel Ricklin, Antonio M Risitano, Ronald P Taylor, Alberto Mantovani, John P A Ioannidis, John D Lambris,

Nat. Immunol. (Nature immunology)
[2019, 20(11):1409-1413]

Cited: 0 times

View full text PDF listing >>



Comparison of RNA-seq and microarray platforms for splice event detection using a cross-platform algorithm.

Juan P Romero, María Ortiz-Estévez, Ander Muniategui, Soraya Carrancio, Fernando J de Miguel, Fernando Carazo, Luis M Montuenga, Remco Loos, Rubén Pío, Matthew W B Trotter, Angel Rubio,

BACKGROUND:RNA-seq is a reference technology for determining alternative splicing at genome-wide level. Exon arrays remain widely used for the analysis of gene expression, but show poor validation rate with regard to splicing events. Commercial arrays that include probes within exon junctions have been developed in order to overcome this problem. ... Read more >>

BMC Genomics (BMC genomics)
[2018, 19(1):703]

Cited: 3 times

View full text PDF listing >>



Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, Mohamed R Daha, Brian V Geisbrecht, Berhane Ghebrehiwet, Piet Gros, George Hajishengallis, V Michael Holers, Markus Huber-Lang, Taroh Kinoshita, Tom E Mollnes, Robert A Montgomery, B Paul Morgan, Bo Nilsson, Ruben Pio, Daniel Ricklin, Antonio M Risitano, Ronald P Taylor, Alberto Mantovani, John P A Ioannidis, John D Lambris,

An amendment to this paper has been published and can be accessed via a link at the top of the paper. ... Read more >>

Nat. Immunol. (Nature immunology)
[2019, 20(11):1556]

Cited: 0 times

View full text PDF listing >>



YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.

Irati Garmendia, María J Pajares, Francisco Hermida-Prado, Daniel Ajona, Cristina Bértolo, Cristina Sainz, Amaya Lavín, Ana B Remírez, Karmele Valencia, Haritz Moreno, Irene Ferrer, Carmen Behrens, Myriam Cuadrado, Luis Paz-Ares, Xosé R Bustelo, Ignacio Gil-Bazo, Daniel Alameda, Fernando Lecanda, Alfonso Calvo, Enriqueta Felip, Montse Sánchez-Céspedes, Ignacio I Wistuba, Rocio Granda-Diaz, Juan Pablo Rodrigo, Juana María García-Pedrero, Ruben Pio, Luis M Montuenga, Jackeline Agorreta,

Rationale: The characterization of new genetic alterations is essential to assign effective personalized therapies in non-small cell lung cancer (NSCLC). Furthermore, finding stratification biomarkers is essential for successful personalized therapies. Molecular alterations of YES1, a member of the SRC (proto-oncogene tyrosine-protein kinase Src) family kinases (SFKs), can be found in ... Read more >>

Am. J. Respir. Crit. Care Med. (American journal of respiratory and critical care medicine)
[2019, 200(7):888-899]

Cited: 2 times

View full text PDF listing >>



Complementing the Cancer-Immunity Cycle.

Ruben Pio, Daniel Ajona, Sergio Ortiz-Espinosa, Alberto Mantovani, John D Lambris,

Reactivation of cytotoxic CD8+ T-cell responses has set a new direction for cancer immunotherapy. Neutralizing antibodies targeting immune checkpoint programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have been particularly successful for tumor types with limited therapeutic options such as melanoma and lung cancer. However, reactivation of T ... Read more >>

Front Immunol (Frontiers in immunology)
[2019, 10:774]

Cited: 2 times

View full text PDF listing >>



Complement in Metastasis: A Comp in the Camp.

Daniel Ajona, Sergio Ortiz-Espinosa, Ruben Pio, Fernando Lecanda,

The complement system represents a pillar of the innate immune response. This system, critical for host defense against pathogens, encompasses more than 50 soluble, and membrane-bound proteins. Emerging evidence underscores its clinical relevance in tumor progression and its role in metastasis, one of the hallmarks of cancer. The multistep process ... Read more >>

Front Immunol (Frontiers in immunology)
[2019, 10:669]

Cited: 0 times

View full text PDF listing >>



Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery.

Francisco Exposito, Maria Villalba, Miriam Redrado, Arrate L de Aberasturi, Cristina Cirauqui, Esther Redin, Elizabeth Guruceaga, Carlos de Andrea, Silvestre Vicent, Daniel Ajona, Luis M Montuenga, Ruben Pio, Alfonso Calvo,

High mortality rates caused by NSCLC show the need for the identification of novel therapeutic targets. In this study we have investigated the biological effects and molecular mechanisms elicited by TMPRSS4 in NSCLC. Overexpression of TMPRSS4 in LKR13 cells increased malignancy, subcutaneous tumor growth and multiorganic metastasis. In conditional knock-down (KD) ... Read more >>

Cancer Lett. (Cancer letters)
[2019, 453:21-33]

Cited: 2 times

View full text PDF listing >>



Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer.

Mohamed Elgendy, Juan Pablo Fusco, Victor Segura, Maria Dolores Lozano, Saverio Minucci, Jose Ignacio Echeveste, Alfonso Gurpide, Mapi Andueza, Ignacio Melero, Miguel F Sanmamed, Maria Rodriguez Ruiz, Alfonso Calvo, Juan Ignacio Pascual, Jose María Velis, Bernardino Miñana, Ricardo Diez Valle, Ruben Pio, Jackeline Agorreta, Marta Abengozar, Maurizio Colecchia, Silvia Brich, Salvatore Lorenzo Renne, Elisabet Guruceaga, Ana Patiño-García, Jose Luis Perez-Gracia,

Sunitinib is one of the most widely used targeted therapeutics for renal cell carcinoma (RCC), but acquired resistance against targeted therapies remains a major clinical challenge. To dissect mechanisms of acquired resistance and unravel reliable predictive biomarkers for sunitinib in RCC, we sequenced the exons of 409 tumor-suppressor genes and ... Read more >>

Int. J. Cancer (International journal of cancer)
[2019, 145(7):1991-2001]

Cited: 0 times

View full text PDF listing >>



5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.

Elena Martínez-Terroba, Carmen Behrens, Jackeline Agorreta, Eduard Monsó, Laura Millares, Enriqueta Felip, Rafael Rosell, José Luis Ramirez, Ana Remirez, Wenceslao Torre, Ignacio Gil-Bazo, Miguel A Idoate, Juan P de-Torres, Ruben Pio, Ignacio I Wistuba, María J Pajares, Luis M Montuenga,

INTRODUCTION:Prognostic biomarkers have been very elusive in the lung squamous cell carcinoma (SCC) and none is currently being used in the clinical setting. We aimed to identify and validate the clinical utility of a protein-based prognostic signature to stratify patients with early lung SCC according to their risk of recurrence ... Read more >>

Thorax (Thorax)
[2019, 74(4):371-379]

Cited: 0 times

View full text PDF listing >>



Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.

Luis M Seijo, Nir Peled, Daniel Ajona, Mattia Boeri, John K Field, Gabriella Sozzi, Ruben Pio, Javier J Zulueta, Avrum Spira, Pierre P Massion, Peter J Mazzone, Luis M Montuenga,

The present review is an update of the research and development efforts regarding the use of molecular biomarkers in the lung cancer screening setting. The two main unmet clinical needs, namely, the refinement of risk to improve the selection of individuals undergoing screening and the characterization of undetermined nodules found ... Read more >>

J Thorac Oncol (Journal of Thoracic Oncology)
[2019, 14(3):343-357]

Cited: 11 times

View full text PDF listing >>



The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer.

Elena Martínez-Terroba, Teresa Ezponda, Cristina Bértolo, Cristina Sainz, Ana Remírez, Jackeline Agorreta, Irati Garmendia, Carmen Behrens, Ruben Pio, Ignacio I Wistuba, Luis M Montuenga, María J Pajares,

In recent years, the relevance of RNA metabolism has been increasingly recognized in a variety of diseases. Modifications in the levels of RNA-binding proteins elicit changes in the expression of cancer-related genes. Here we evaluate whether SRSF1 regulates the expression of DNA repair genes, and whether this regulation has a ... Read more >>

Lab. Invest. (Laboratory investigation; a journal of technical methods and pathology)
[2018, 98(12):1562-1574]

Cited: 1 time

View full text PDF listing >>



A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.

Elena Martínez-Terroba, Carmen Behrens, Fernando J de Miguel, Jackeline Agorreta, Eduard Monsó, Laura Millares, Cristina Sainz, Miguel Mesa-Guzman, José Luis Pérez-Gracia, María Dolores Lozano, Javier J Zulueta, Ruben Pio, Ignacio I Wistuba, Luis M Montuenga, María J Pajares,

Each of the pathological stages (I-IIIa) of surgically resected non-small-cell lung cancer has hidden biological heterogeneity, manifested as heterogeneous outcomes within each stage. Thus, the finding of robust and precise molecular classifiers with which to assess individual patient risk is an unmet medical need. Here, we identified and validated the ... Read more >>

J. Pathol. (The Journal of pathology)
[2018, 245(4):421-432]

Cited: 1 time

View full text PDF listing >>



Telomere length, COPD and emphysema as risk factors for lung cancer.

Juan P de-Torres, Pablo Sanchez-Salcedo, Gorka Bastarrika, Ana B Alcaide, Rubén Pío, María Jose Pajares, Arantza Campo, Juan Berto, Luis Montuenga, Maria Del Mar Ocon, Carmen Monente, Bartolome R Celli, Javier J Zulueta,

Eur. Respir. J. (The European respiratory journal)
[2017, 49(1):]

Cited: 4 times

View full text PDF listing >>



Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer.

Juan Pablo Fusco, Guillermo Pita, María José Pajares, Maria Pilar Andueza, Ana Patiño-García, Juan P de-Torres, Alfonso Gurpide, Javier Zulueta, Rosario Alonso, Nuria Alvarez, Ruben Pio, Ignacio Melero, Miguel F Sanmamed, Maria Rodriguez Ruiz, Ignacio Gil-Bazo, Jose María Lopez-Picazo, Ciro Casanova, Rebeca Baz Davila, Antonio Agudo, Maria Dolores Lozano, Alvaro Gonzalez, Nuria Sala, Eva Ardanaz, Javier Benitez, Luis Montuenga, Anna Gonzalez-Neira, Jose Luis Perez-Gracia,

Single nucleotide polymorphisms (SNPs) may modulate individual susceptibility to carcinogens. We designed a genome-wide association study to characterize individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small cell lung cancer (NSCLC), and we validated our results. We hypothesized that this strategy would enrich the frequencies of ... Read more >>

Cancer Med (Cancer medicine)
[2018, :]

Cited: 0 times

View full text PDF listing >>



The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.

Cherine Abou Faycal, Elisabeth Brambilla, Jackeline Agorreta, Nina Lepeltier, Thibault Jacquet, Nicolas Lemaître, Anouk Emadali, Anthony Lucas, Pedro M Lacal, Luis Montuenga, Ruben Pio, Sylvie Gazzeri, Beatrice Eymin,

BACKGROUND:While lung adenocarcinoma patients can somewhat benefit from anti-angiogenic therapies, patients with squamous cell lung carcinoma (SQLC) cannot. The reasons for this discrepancy remain largely unknown. Soluble VEGF receptor-1, namely sVEGFR1-i13, is a truncated splice variant of the cell membrane-spanning VEGFR1 that has no transmembrane or tyrosine kinase domain. sVEGFR1-i13 ... Read more >>

Br. J. Cancer (British journal of cancer)
[2018, 118(12):1596-1608]

Cited: 2 times

View full text PDF listing >>



Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.

Daniel Ajona, Carolina Zandueta, Leticia Corrales, Haritz Moreno, María J Pajares, Sergio Ortiz-Espinosa, Elena Martínez-Terroba, Naiara Perurena, Fernando J de Miguel, Eloisa Jantus-Lewintre, Carlos Camps, Silvestre Vicent, Jackeline Agorreta, Luis M Montuenga, Ruben Pio, Fernando Lecanda,

RATIONALE:C5aR1 (CD88), a receptor for complement anaphylatoxin C5a, is a potent immune mediator. Its impact on malignant growth and dissemination of non-small cell lung cancer cells is poorly understood. OBJECTIVES:To investigate the contribution of the C5a/C5aR1 axis to the malignant phenotype of non-small cell lung cancer cells, particularly in skeletal ... Read more >>

Am. J. Respir. Crit. Care Med. (American journal of respiratory and critical care medicine)
[2018, 197(9):1164-1176]

Cited: 6 times

View full text PDF listing >>



Complement C4d-specific antibodies for the diagnosis of lung cancer.

Daniel Ajona, Marcin Okrój, María J Pajares, Jackeline Agorreta, María D Lozano, Javier J Zulueta, Carla Verri, Luca Roz, Gabriella Sozzi, Ugo Pastorino, Pierre P Massion, Luis M Montuenga, Anna M Blom, Ruben Pio,

Development of molecular markers that help to identify high-risk individuals or diagnose indeterminate pulmonary nodules could have a major impact on lung cancer clinical management. In this study, we evaluated the diagnostic potential of a newly-developed ELISA that specifically detects complement C4d. We measured this marker in five independent cohorts ... Read more >>

Oncotarget (Oncotarget)
[2018, 9(5):6346-6355]

Cited: 6 times

View full text PDF listing >>



Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment.

Daniel Ajona, Sergio Ortiz-Espinosa, Ruben Pio,

Recent insights into the role of complement anaphylatoxins C3a and C5a in cancer provide new opportunities for the development of innovative biomarkers and therapeutic strategies. These two complement activation products can maintain chronic inflammation, promote an immunosuppressive microenvironment, induce angiogenesis, and increase the motility and metastatic potential of cancer cells. ... Read more >>

Semin. Cell Dev. Biol. (Seminars in cell & developmental biology)
[2019, 85:153-163]

Cited: 6 times

View full text PDF listing >>



Comparison of RNA-seq and Microarray Platforms for Splice Event Detection using a Cross-Platform Algorithm

Juan Romero, María Ortiz-Estévez, Ander Muniategui, Soraya Carrancio, Fernando de Miguel, Fernando Carazo, Luis Montuenga, Remco Loos, Rubén Pío, Matthew Trotter, Angel Rubio,

Abstract RNA-seq is a reference technology for determining alternative splicing at genome-wide level. Exon arrays remain widely used for the analysis of gene expression, but show poor validation rate with regard to splicing events. Commercial arrays that include probes within exon junctions have been developed in order to overcome this ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.

Daniel Ajona, Sergio Ortiz-Espinosa, Haritz Moreno, Teresa Lozano, María J Pajares, Jackeline Agorreta, Cristina Bértolo, Juan J Lasarte, Silvestre Vicent, Kai Hoehlig, Axel Vater, Fernando Lecanda, Luis M Montuenga, Ruben Pio,

Disruption of the programmed cell death protein 1 (PD-1) pathway with immune checkpoint inhibitors represents a major breakthrough in the treatment of non-small cell lung cancer. We hypothesized that combined inhibition of C5a/C5aR1 and PD-1 signaling may have a synergistic antitumor effect. The RMP1-14 antibody was used to block PD-1, ... Read more >>

Cancer Discov (Cancer discovery)
[2017, 7(7):694-703]

Cited: 32 times

View full text PDF listing >>



Innate immune mediators in cancer: between defense and resistance.

Pedro Berraondo, Luna Minute, Daniel Ajona, Leticia Corrales, Ignacio Melero, Ruben Pio,

Chronic inflammation in the tumor microenvironment and evasion of the antitumor effector immune response are two of the emerging hallmarks required for oncogenesis and cancer progression. The innate immune system not only plays a critical role in perpetuating these tumor-promoting hallmarks but also in developing antitumor adaptive immune responses. Thus, ... Read more >>

Immunol. Rev. (Immunological reviews)
[2016, 274(1):290-306]

Cited: 27 times

View full text PDF listing >>



Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Jose Luis Perez-Gracia, Miguel F Sanmamed, Ana Bosch, Ana Patiño-Garcia, Kurt A Schalper, Victor Segura, Joaquim Bellmunt, Josep Tabernero, Christopher J Sweeney, Toni K Choueiri, Miguel Martín, Juan Pablo Fusco, Maria Esperanza Rodriguez-Ruiz, Alfonso Calvo, Celia Prior, Luis Paz-Ares, Ruben Pio, Enrique Gonzalez-Billalabeitia, Alvaro Gonzalez Hernandez, David Páez, Jose María Piulats, Alfonso Gurpide, Mapi Andueza, Guillermo de Velasco, Roberto Pazo, Enrique Grande, Pilar Nicolas, Francisco Abad-Santos, Jesus Garcia-Donas, Daniel Castellano, María J Pajares, Cristina Suarez, Ramon Colomer, Luis M Montuenga, Ignacio Melero,

The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. This has led to the proliferation of a myriad of exploratory studies using ... Read more >>

Cancer Treat. Rev. (Cancer treatment reviews)
[2017, 53:79-97]

Cited: 18 times

View full text PDF listing >>



A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.

Fernando J de Miguel, María J Pajares, Elena Martínez-Terroba, Daniel Ajona, Xabier Morales, Ravi D Sharma, Francisco J Pardo, Ana Rouzaut, Angel Rubio, Luis M Montuenga, Ruben Pio,

Increasing interest has been devoted in recent years to the understanding of alternative splicing in cancer. In this study, we performed a genome-wide analysis to identify cancer-associated splice variants in non-small cell lung cancer. We discovered and validated novel differences in the splicing of genes known to be relevant to ... Read more >>

Mol Oncol (Molecular oncology)
[2016, 10(9):1437-1449]

Cited: 17 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0713 s